Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06181188 · ClinicalTrials.gov registry record · Phase 4
Use of Ketamine for Conscious Sedation in Flexible Bronchoscopy
A Phase 4 study, sponsored by Brooke Army Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 66
- Enrollment target
NCT06181188: Completed Phase 4 study, sponsored by Brooke Army Medical Center.
NCT06181188 is a Phase 4 study that has completed, run by Brooke Army Medical Center. The registered enrollment target is 66 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06181188, a Phase 4 study, has completed, sponsored by Brooke Army Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 66 participants
- Enrollment target
Study Summary
In this study, the investigators plan to conduct a single blinded randomized controlled trial in the Pulmonary Service to demonstrate the efficacy of ketamine and its utility in moderate sedation. Patients presenting for bronchoscopy who meet inclusion criteria will be approached, and if amenable, will be consented and enrolled. Patients will be randomized to receive either 1 mg of midazolam and ketamine 0.25 to 0.5 mg/kg loading dose with subsequent doses of 10-20 mg IV or standard fentanyl and midazolam in 25mcg and 1mg increments respectively for moderate sedation during their procedure. The primary outcome will be patient satisfaction, which will be measured a using patient clinical satisfaction form. A number of secondary outcomes will include the following: (1) provider satisfaction (2) the time from sedation administration to procedure start (when the scope is inserted), (3) the time from sedation to scope removal from the trachea (4) the time from sedation to discharge (defined as the time from the end of the procedure until the patient meets discharge criteria from the recovery area), (5) total dose of medications given (including midazolam, fentanyl, and ketamine), (6) adverse events, (7) vital signs, (8) and the need for additional medications, in particular reversal agents.
Primary Outcome
A twenty one question survey assessing patient satisfaction using a 7-point Likert Scale. A "1" on the scale would indicated very satisfied, 2 - satisfied, 3 - somewhat satisfied, 4 - neither satisfied nor dissatisfied, 5 - somewhat dissatisfied, 6 - dissatisfied, and 7- very dissatisfied.
Interventions
- DRUG Ketamine
- DRUG Midazolam
- DRUG Fentanyl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2019-07-15 |
| Est. Completion | 2023-10-30 |
| Phase | Phase 4 |
What the finished NCT06181188 record still lists
NCT06181188 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 3 interventions - of which Ketamine is the first listed.
NCT06181188 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06181188 about?
NCT06181188 is a clinical study titled "Use of Ketamine for Conscious Sedation in Flexible Bronchoscopy". In this study, the investigators plan to conduct a single blinded randomized controlled trial in the Pulmonary Service to demonstrate the efficacy of ketamine and its utility in moderate sedation. Patients presenting for bronchoscopy who meet inclusion criteria will be approached, and if amenable, w...
What is the current status of trial NCT06181188?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 66 participants. The study started on 2019-07-15. Estimated completion is 2023-10-30.
What interventions are being tested in trial NCT06181188?
The interventions under investigation include: Ketamine (DRUG), Midazolam (DRUG), Fentanyl (DRUG).
Who is sponsoring clinical trial NCT06181188?
This trial is sponsored by Brooke Army Medical Center, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06181188's enrollment target sits among peer trials
66 1083rd of 2000 higher than 910 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI